Navigation Links
Rigel Earns Milestone Payments From AstraZeneca
Date:9/29/2010

une inflammatory disease that causes damage to the joints and other organs. It is a major cause of disability, affecting approximately 1 in 100 people, and is also associated with reduced life expectancy, especially if not adequately treated.

Fostamatinib, which has completed a comprehensive phase 2 program, is the first oral spleen tyrosine kinase (syk) inhibitor in development as a novel therapeutic approach for RA. Inhibiting syk is thought to block signaling in multiple cell types involved in inflammation and tissue degradation in RA.   Inhibition of syk signaling is therefore believed to be a very attractive research approach to RA treatment.

About Rigel Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune disorders, as well as muscle and metabolic diseases. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib (R788), an oral syk inhibitor that has started its phase 3 clinical trial program for rheumatoid arthritis, and R343, an inhaled syk inhibitor that is in clinical trials for asthma.

Rigel Forward-Looking StatementsThis press release contains "forward-looking" statements, including, without limitation, statements related to the scope of the phase 3 clinical program of R788 (fostamatinib) and the filing of new drug applications, including the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "expected", "believed" and similar expressions are intended to identify these forward-looking statements. These forward-looking stateme
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Rigel to Host Update Conference Call
2. Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
3. Rigel to Present at the 2008 Credit Suisse Healthcare Conference
4. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
5. Rigel to Participate at the RBC Capital Markets Healthcare Conference
6. Rigel to Present at Citis Biotech Day
7. Rigel Announces First Quarter 2009 Financial Results
8. Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
9. Aerospace engineer earns Oak Ridge Associated Universities Ralph Powe Junior Faculty Award
10. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
11. Advanced Pest Control Earns Quality Pro Designation for General Pest Control Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 The UPMC Center ... 2015 Fellows in the Emerging Leaders in Biosecurity Initiative ... leaders in the field of biosecurity, UPMC has selected ... a wide array of backgrounds, including biological science, medicine, ... "With the vision and support of ...
(Date:3/4/2015)... 2015 USDM Life Sciences , ... sciences industry, hired David Blewitt as Vice ... Compliance Services and Solutions at USDM Life Sciences , ... while maintaining compliance with government regulations worldwide. , ... accomplished life sciences regulatory and IS compliance professional with ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biologics and Biosimilars Industry Report ... The Global Biologics and Biosimilars Industry ... on the current state of the biologics and ... basic overview of the industry including definitions, classifications, ...
(Date:3/4/2015)... 04, 2015 PRC Clinical, ... San Francisco Bay Area, will exhibit and present at ... 2015 on March 25th and 26th in Tel ... relationships with Israeli life science companies seeking to conduct ... company’s services span all phases of human trials, from ...
Breaking Biology Technology:UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Global Biologics and Biosimilars Industry Report 2015-2020 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4
... is crucial to preventing countless human diseases. In a ... discovered a new approach for studying molecules within their ... of how bacteria infect people. The research, led ... published in the Proceedings of the National Academy ...
... American Ceramic Society (ACerS) today announced the names of ... B. Marshall and Koichi Niihari are the 2011 recipients ... accorded members of ACerS. The award is given in ... and glass profession. "The Society,s Distinguished Life Member ...
... China Cord Blood Corporation (NYSE: CO ) ("CCBC" ... laboratory testing, hematopoietic stem cell processing, and stem cell storage ... first quarter of fiscal year 2012, which ended June 30, ... of Fiscal 2012Highlights Revenue ...
Cached Biology Technology:Scientists develop new technologies for understanding bacterial infections 2Scientists develop new technologies for understanding bacterial infections 3The American Ceramic Society selects Marshall, Niihara as 2011 Distinguish Life Members 2China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2012 2China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2012 3China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2012 4China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2012 5China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2012 6China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2012 7China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2012 8China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2012 9China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2012 10
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... Boston, MA Tuesday, March 3, 2015 at 11.20 ... Orlando, FL Wednesday, March 4, 2015 ... To access the live webcasts for these events, please visit ...
(Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
(Date:2/5/2015)... Feb. 5, 2015  Marken is starting its 35 ... has launched a new marketing campaign to solidify its ... The new campaign focuses on First as ... shipments. The first headline in the series, ... priorities with its client,s priorities. Marken recognizes the need ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... TORONTO, ON Psychologists at the University of ... interaction has the ability to influence an individual,s sensitivity ... clinical implications for doctor-patient relationships and the general well-being ... of studies over the past several decades have demonstrated ...
... CHICAGO --- Northwestern Medicine researchers at the Robert H. ... a new, nontoxic drug made from a chemical in soy ... to the rest of the body. These findings will ... Research Frontiers in Cancer Prevention Research Conference. Genistein, a ...
... at the University of California, San Diego School of ... of federally approved drugs to more than 1,000 proteins ... opening new avenues to repurpose these drugs to treat ... PLoS Computational Biology . "Tuberculosis is currently ...
Cached Biology News:Psychologists identify influence of social interaction on sensitivity to physical pain 2Soy may stop prostate cancer spread 2TB-drugome provides new targets for anti-tuberculosis drug discovery 2
... The BioGenex VISION Sytem is ... that comes with proprietary digital imaging ... for digital image acquisition, analysis, archving/retrieval ... is a state-of-the-art digital imaging system ...
... -mr agarose is specifically for ... endoosmosis, and is recommended for ... weight proteins or complexes that ... of molecular sieving in polyacrylamide ...
... is used for second-dimension SDS-PAGE sample ... place in PROTEAN Plus cells. Bromophenol ... allow monitoring of electrophoresis runs. The ... in 1x Tris, glycine, SDS, and ...
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
Biology Products: